Johnson & Johnson Innovation – JJDC

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Flindr Therapeutics is a precision oncology therapeutics company based in the Netherlands. Founded in 2020 as a spin-out from the Netherlands Cancer Institute (NKI) and Oncode Institute, the company discovers and develops precision oncology therapeutics with the potential to eradicate tumors in specific patient populations. Flindr's lead program is a first-in-class small molecule inhibitor targeting RNF31 (HOIP), a protein-stabilizing E3 ubiquitin ligase aberrantly activated in solid and hematological malignancies. The company has obtained promising preclinical activity for this drug candidate in ovarian cancer and B-cell lymphoma models. It has also identified biomarkers to help select patients most likely to respond to RNF31 inhibitor treatment. Flindr leverages the "ImmunoGram Drug Discovery Engine," an approach involving reverse-translating tumor-specific and host-specific heterogeneity observed in clinical patients into lab models. This facilitates the screening and selection of crucial drug targets involved in patient clinical responses. The company combines expertise in translational biology, cancer target identification, immuno-oncology, and small molecule oncology drug development. Its team has a successful track record in developing covalent small molecule inhibitors from discovery to market approval.

Ribon Therapeutics is a biotechnology company focused on developing therapeutics that target novel enzyme families activated under cellular stress conditions contributing to disease. As of January 2023, Ribon’s portfolio included two oral, potentially first-in-class clinical programs: RBN-2397, a PARP7 inhibitor, and RBN-3143, a PARP14 inhibitor, with broad potential applications in oncology and inflammatory diseases, respectively. The company aims to develop effective treatments for patients with limited therapeutic options by exploring novel areas of biology.Utilizing its proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform, Ribon is creating a pipeline of selective, small molecule inhibitors for numerous NAD+-utilizing enzymes, starting with monoARTs (mono-ADP-ribosyltransferase), which have applications across various therapeutic areas.

ONL Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for protecting and improving the vision of patients with retinal diseases. The company's primary focus is on advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, which is the root cause of vision loss and blindness across various retinal conditions. ONL Therapeutics' lead product, ONL1204 Ophthalmic Solution, is a first-in-class small molecule Fas inhibitor designed as a neuroprotectant for key retinal cells, including photoreceptors.
ONL1204 is being developed for multiple retinal conditions. In February 2023, the US Food and Drug Administration (FDA) authorized the company to proceed with an Investigational New Drug (IND) application for ONL1204 Ophthalmic Solution. The company initiated a Phase 2 clinical study of ONL1204 in patients with macula-off rhegmatogenous retinal detachment (RRD) in the US in April 2023. This randomized, controlled study aims to enroll 135 patients across three arms, evaluating the safety and efficacy of a single intravitreal injection of ONL1204 as an adjunct to standard-of-care surgical repair.
In addition to RRD, ONL Therapeutics is conducting Phase 1 billion clinical trials for ONL1204 in patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD) and progressing open-angle glaucoma in Australia and New Zealand. Preliminary results from the Phase 1 billion trial in GA associated with dry AMD showed promising outcomes, with patients treated with ONL1204 demonstrating reductions in the rate of growth of the GA lesion after six months of treatment compared to sham patients. The company is also exploring the potential of ONL1204 in other retinal conditions, including inherited retinal degeneration (IRD), also known as retinitis pigmentosa.
ONL Therapeutics is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD, and IRD. The company's unique approach to preserving vision through Fas inhibition has the potential to address significant unmet medical needs in the field of ophthalmology.

Iterative Scopes focuses on applying AI-based precision medicine to gastroenterology, aiming to optimize clinical trials for inflammatory bowel disease (IBD) treatments. Their technology is also designed to potentially improve colorectal cancer screenings. With proprietary AI and computer vision technologies, Iterative Scopes aims to enhance the accuracy and consistency of endoscopy readings. Initially, they are focusing on improving polyp detection for colorectal cancer screenings and standardizing disease severity characterization for IBD. In the long term, the company plans to establish more meaningful endpoints for gastrointestinal diseases, which could better predict therapeutic responses and disease outcomes. Founded in 2017 as a spin-off from MIT, Iterative Scopes is based in Cambridge, Massachusetts.April 2022, the company acquired two clinical trial optimization companies, Clinical Research Strategy Group and Precision Research as part of its plans to strengthen ties with the IBD clinical research community and research sites.Key customers and partnershipsThe MIT spinout has partnered with Jonhson and Johnson’s Janssen R&amp;D division to improve its own clinical trials for treatments of IBD as well as Janssen’s trials for treating Crohn’s disease and ulcerative colitis, which are two main types of IBD. Its software automatically analyzes images and videos collected during colonoscopies, allowing researchers to set a standard benchmark for their trial participants when filtering through submitted data to find eligible patients. In Iterative Scopes partnered with Eli Lilly and Company in February 2021 to advance AI applications for IBD clinical trials. In October 2022, the company partnered with One GI, a gastroenterology management services organization (MSO), to bring its AI Recruitment (AIR) technology to One GI’s clinical research. Initially, One GI was expected to use AIR at Gastro One, one of One GI’s clinical research sites in Memphis, Tennessee, with plans to expand to additional research sites within the One GI network. The implementation of AIR was expected to aid in the recruitment of patients for clinical trials focused on IBD.

<div>
 
 Rapport Therapeutics is a clinical stage biotechnology company that develops small molecule drugs to treat neurological disorders. Rapport's platform uses receptor-associated proteins (RAPs) to enable the discovery of small molecule drugs that target specific subsets of neurons where neurological disorders originate. The company had aimed to use its platform to improve efficacy and limit side effects compared to traditional neuroactive medicines.&nbsp;
 
 
 
 
 The company&rsquo;s first program using its RAP platform is developed to treat drug-resistant seizure disorders and is in Phase I clinical trials.&nbsp;
 
 
 
 
 
 Funding and financials
 
 
 In August 2023, the company raised USD 150 million in a 
 <a href="https://sp-edge.com/updates/21266">
 Series B
 </a>
 funding round led by Cormorant Asset Management, &nbsp;The funds were used for the advancement of Rapport's pipeline of precision neurology drugs and expand into new indications using its receptor-targeting platform.
 
 
 
 
 
</div>

Novel therapies to reboot cells and organs

Cell & Gene Therapy

S onoThera is a biotechnology company that develops novel gene therapies for various diseases using ultrasound-guided nonviral delivery. The company’s main therapeutics are based on the sonoporation technology, which uses microbubbles and ultrasound to deliver nucleic acid payloads to the patient’s own cells, activating a therapeutic response. The company claims that their ultrasound-guided nonviral gene delivery platform is the first of its kind.As of May 2024, the company had not disclosed its clinical pipeline.Key customers and partnershipsThe company partnered with Janssen Pharmaceuticals, part of the Johnson &amp; Johnson group, in May 2023 to collaborate on developing a novel approach for delivering DNA- and RNA-based nucleic acid-based therapeutics through the use of SonoThera's ultrasound-guided nonviral gene delivery platform.

UK-based AviadoBio is a developer of gene-based therapeutics that target neurodegenerative disorders. Specifically, the company develops therapeutics that help treat patients with conditions such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). AviadoBio’s platform uses therapeutics based on gene supplementation and gene knock-down and is based on research carried out at King’s College London and the UK Dementia Research Institute.As of May 2024, the company had five therapeutic candidates; its lead candidate, AVB-101 for the testing of frontotemporal dementia with GRN mutations, was in its early clinical testing phase. The company’s other candidates were all in discovery stages for the treatment of ALS and Frontotemporal disorders. In April 2024, the company announced that the first patient had been treated with its AVB-101 candidate for frontotemporal dementia with GRN mutations as a part of its Phase I/II clinical trial.

Astraveus is a biotechnology company that develops modular, microfluidic cell foundries for cell and gene therapy (CGT) manufacturing. Astraveus’s main therapeutics are CAR-T cells and hematopoietic stem cells (HSCs), which are genetically engineered to target and treat various diseases, such as cancer, hemoglobinopathies, and immune deficiencies. Astraveus uses its Lakhesys platform, an end-to-end cell foundry that uses single-use, microfluidic bioprocessors, to optimize and miniaturize the production of these therapeutics. The company claims that the Lakhesys platform is the world’s first cell foundry.As of May 2024, Astraveus had not disclosed its clinical pipeline.

Capstan Therapeutics is a developer of cell-based therapeutic platforms for the treatment of diseases related to oncology, autoimmune disorders, fibrosis, and monogenic blood disorders. Launched in September 2022, Capstan’s therapeutics use targeted lipid nanoparticles (tLNP) as a delivery mechanism for either mRNA or gene editing solutions. The company’s solutions are capable of reprogramming specific cells in-vivo, allowing for therapeutics to either target pathogenic cells or engineer immune cells. As of May 2024, the company had not publicly disclosed its clinical pipeline.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

<div>
 
 Paige offers an AI-powered pathology computational platform for detecting cancer subtypes, enabling pathologists to make accurate digital diagnoses. The company claims its deep-learning algorithms have detected prostate cancer, skin cancer, and breast cancer accurately.&nbsp;
 
 
 Paige's platform can be used to access proprietary data to generate and test digital biomarker hypotheses and also for SaaS-based deployment of digital biomarkers to identify patients for therapies and clinical trials, as well as cancer detection. Paige is the first company to receive FDA&rsquo;s breakthrough designation in 2019 for one of its pathology products, a prostate module. In 
 <a href="https://sp-edge.com/updates/23180">
 October 2023
 </a>
 , it received another breakthrough device designation from the FDA for its breast cancer detection tool, Paige Lymph Node.
 
 
 Key customers and partnerships
 
 
 The company started commercializing its Paige Prostate from 2019, which is a first-to-market prostate cancer detection solution. Its AI solutions are vendor-agnostic, which allows Paige to cater to a broad range of customers.&nbsp;
 
 
 The company collaborated with several companies, including 
 <a href="https://invicro.com/invicro-and-paige-partner-to-offer-comprehensive-tissue-biomarker-profiling-services/">
 Invicro LLC 
 </a>
 (January 2020), 
 <a href="https://sp-edge.com/updates/11137">
 Janssen
 </a>
 (June 2022), 
 <a href="https://sp-edge.com/updates/13275">
 OptraSCAN
 </a>
 (September 2022), 
 <a href="https://sp-edge.com/updates/17043">
 Leica Biosystem
 </a>
 s (March 2023), 
 <a href="https://sp-edge.com/updates/21127">
 Ohio State University&rsquo;s Wexner Medical Center 
 </a>
 (August 2023), and 
 <a href="https://sp-edge.com/updates/21665">
 Microsoft
 </a>
 (September 2023). 
 Funding and financials
 
 
 The company closed a USD 220 million 
 <a href="https://www.businesswire.com/news/home/20210309005546/en/Paige-Secures-Financing-from-KKR-for-Total-Series-C-Funding-Round-of-Over-125-Million">
 Series C
 </a>
 funding in March&nbsp; 2021, co-led by Casdin Capital, Johnson and Johnson Innovation (JJDC) and Kolberg KravisRoberts, with plans to expand geographically and grow further develop clinical applications, biomarkers, and AI-based diagnostics.
 
</div>

<div>
 
 Spun out of the Massachusetts Institute of Technology (MIT) in 2017, Iterative Scopes offers AI-based technology and software solutions to assist precision medicine developers in the area of gastroenterology with a focus on inflammatory bowel disease (IBD) and colorectal cancer prevention. The company&rsquo;s platforms enable cancer screenings, endoscopy readings, and also support clinical trial recruitment.
 
 
 The company offers an AI-driven clinical trial recruitment service incorporating algorithms to assist pharmaceutical companies to identify and classify patients to meet the clinical trial requirement. It also plans to build digital endpoints and biomarkers to be used in clinical trials and drug development.&nbsp;
 
 
 The company&rsquo;s AI medical device SKOUT, which is CE certified, uses computer vision technology and AI that identifies important areas during endoscopy. The device is available in Europe and not yet sold in the US as it is under review by FDA.
 
 
 In 
 <a href="https://sp-edge.com/updates/10029">
 April 2022
 </a>
 , the company acquired two clinical trial optimization companies, Clinical Research Strategy Group and Precision Research, to support the drug development process for IBD.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company has secured partnerships with Pfizer (February 2022) to gain access to one of Pfizer&rsquo;s IBD clinical trial databases and Provation (March 2021), a workflow provider, to convert the data derived from the endoscopy findings into text for clinical reports and health records.
 
 
 Funding and financials
 
 
 In 
 <a href="https://sp-edge.com/updates/7916">
 January 2022
 </a>
 , Iterative Scopes raised USD 150 million in a 
 <a href="https://sp-edge.com/updates/7916">
 Series B funding
 </a>
 round co-led by Insight Partners and Clearlake Capital Group. The proceeds were directed toward further developing the company&rsquo;s AI-driven technologies, expanding its product offerings, and increasing its technical and clinical operations team sizes.
 
</div>

<div>
 
 Verana Health is a clinical data analytics company that offers AI and machine learning-based data platforms focused on supporting pharmaceutical companies and drug developers by providing data-driven insights across medical areas such as neurology, urology, and ophthalmology.&nbsp;
 
 
 The company has two flagship products: 1) VeraQ, a population health data engine that gathers unstructured medical data to generate insights; 2) Qdata, a database of curated clinical data derived from VeraQ.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company gathers medical data from patient registries and electronic health record (EHR) notes via its partnerships with various medical associations and societies including the American Academy of Ophthalmology, the American Academy of Neurology, and the American Urological Association. The data is then used to generate insights that assist pharma companies to expedite their drug development process, as well as save costs.&nbsp;
 
 
 The company reports that it is working together with various multinational pharma companies and emerging biotechs, although names have not been disclosed. Furthermore, as of March 2024, it had over 20,000 clinicians in its data network.&nbsp;
 
 
 Funding and financials
 
 
 Founded in 2008 as DigiSight Technologies, the company rebranded to Verana Health in 2018 with the backing of GV (formerly Google Ventures). In its latest 
 <a href="https://sp-edge.com/updates/7868">
 Series E funding round
 </a>
 in 
 <a href="https://sp-edge.com/updates/7868">
 January 2022
 </a>
 , Verana raised USD 150 million led by Johnson &amp; Johnson Innovation and Novo Growth. The funds were used to enhance the company&rsquo;s product offerings and its data network and pursue new clinical data partnerships. 
 
</div>

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

SpectraWAVE, founded in 2017 and based in Bedford, Massachusetts, is a medical imaging company focused on improving treatment and outcomes for patients with coronary artery disease (CAD). The company's flagship product is the HyperVue Imaging System, an intravascular imaging system that received FDA 510(k) clearance in March 2023. HyperVue combines next-generation DeepOCT (optical coherence tomography) images and near-infrared spectroscopy (NIRS) to optimize coronary stenting procedures in cardiac catheterization labs.
The HyperVue system utilizes SpectraWAVE's proprietary DeepOCT-NIRS imaging technology, which pushes the limits of optical coherence tomography in both image quality and depth. It features the Starlight Imaging Catheter, a low-profile, no-flush device that delivers rapid pullbacks of both imaging modalities in a single form factor. The system is designed to provide key insights into plaque morphology, guide plaque modification decisions, assist with stent and balloon sizing, and help with landing zone selection.
In September 2023, SpectraWAVE received additional FDA 510(k) clearance for enhancements to the HyperVue system. These include contrast-free saline imaging, artificial intelligence algorithms to support the identification of key clinical structures such as calcium and external elastic lamina, and hands-free angiographic co-registration. The system also incorporates AI-enabled lipid, lumen, stent, and side branch detection.

HistoSonics is a medical device company that develops non-invasive platforms utilizing histotripsy, a novel focused ultrasound therapy. The company's primary product is the Edison Histotripsy System, which received FDA De Novo clearance in October 2023 for the non-invasive destruction of liver tumors. Histotripsy uses focused sound energy to produce controlled acoustic cavitation that mechanically destroys and liquefies targeted tissue at sub-cellular levels without damaging surrounding healthy tissue. The Edison System combines proprietary technology with advanced imaging to deliver personalized, non-invasive treatments with precision and control. It allows physicians to monitor tissue destruction in real-time, offering visualization and control not available with existing modalities. The system achieved a 95.5% technical success rate in clinical trials for precisely targeting and destroying liver tumors. HistoSonics is currently focused on commercializing the Edison System for liver treatments in the US and select global markets while exploring expanded applications for histotripsy in other organs such as the kidney, pancreas, and prostate.
Key customers and partnerships
HistoSonics has partnered with leading institutions across the US and internationally to develop multi-disciplinary histotripsy liver programs. The company conducted clinical trials at 13 sites across the US and Europe, including Mutua Terrassa Hospital and Vall D'Hebron Hospital in Barcelona, Spain. HistoSonics also maintains research collaborations with the University of Michigan, where histotripsy was originally developed, and the University of Wisconsin, which provides critical product development capabilities and validation of the company's non-invasive approach across multiple applications. In August 2024, HistoSonics announced plans to initiate the BOOMBOX Master Study to further evaluate the Edison System for liver tumor treatment across multidisciplinary users.

V-Wave focuses on developing interatrial shunt devices for treating heart failure (HF). Its flagship product, the Ventura Interatrial Shunt, is an investigational device designed in an hourglass shape to reduce elevated left atrial pressure, a key driver of pulmonary congestion and hospitalizations in HF patients. The shunt creates a controlled amount of blood flow between the left and right atria, lowering left atrial pressure while protecting the right heart from volume overload. It is implanted through a minimally invasive catheter-based procedure, with patients typically discharged after an overnight stay.The Ventura Shunt has received breakthrough device designation from the FDA and CE Marking in the EU. As of July 2024, V-Wave was undergoing trial and was yet to obtain FDA approval. In April 2024, V-Wave announced positive results from its RELIEVE-HF trial.

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

<div>
 
 Cue Health (formerly known as Ruubix) is a virtual diagnostics care platform that develops Covid-19 test kits for at-home and clinical use. 
 <a href="https://sp-edge.com/updates/19244">
 In June 2023 
 </a>
 , it received the De Novo authorization, a regulatory pathway provided by the FDA for the approval of new medical devices, for its Cue Covid-19 Molecular Test, making it the first FDA-authorized home use Covid-19 test. Further, according to an independent study by the Mayo Clinic, its tests matched laboratory results with 98% accuracy.
 
 
 The Cue Health Monitoring System consists of a portable reader with a single-use test cartridge, sample collection wands, its Covid-19 test kit, and an accompanying mobile app that displays the digital results of the tested samples within 20 minutes.&nbsp;
 
 
 Additionally, Cue Health offers a D2C virtual care platform, Cue+, as a part of its membership program. The two-tiered membership program includes: 1) Cue+ Essential for USD 49.99 offers access to at-home testing services, on-demand access to chat with physicians consultations, and online prescription service; and 2) Cue+ Complete priced at USD 74.99 will include Cue+Essential services and CDC-compliant COVID-19 test results through in-app video proctoring for travel, work, or school.
 
 
 The company began trading on NASDAQ in September 2021 under the ticker symbol &ldquo;HLTH&rdquo; raising USD 200 million at IPO. In August 2023, the company was awarded a USD 28 million worth contract from the Biomedical Advanced Research and Development Authority to develop multiple over-the-counter and point-of-care tests.&nbsp;
 
 
 In 2022, revenue decreased 22% YoY to USD 483.5 million primarily due to the completion of its US DoD Agreement in December 2021 combined with declining demand for COVID-19 testing.
 
 
 Key customers and partnerships
 
 
 The company has established several key partnerships&nbsp; in the private and public sector, including that with a medication company BioReference Laboratories (April 2022), pharmacy provider Albertsons Companies (March, 2022), University of Pittsburgh Medical Center Children's Community Pediatrics (March, 2022), and pharmaceutical distributor Cardinal Health (February, 2022).
 
</div>

Cala Health develops wearable devices that deliver neuromodulation therapies using electrical nerve stimulation. The company claims its FDA-approved Cala Trio is the first non-invasive prescription therapy proven to reduce essential tremors.Its flagship product, the Cala kIQ System, launched in June 2023, uses Transcutaneous Afferent Patterned Stimulation (TAPS) therapy to combat tremors in people with essential tremor and Parkinson’s disease. The device's features include the ability to create individualized stimulation patterns based on the patient's tremor patterns, ease of use as a wrist-worn wearable, and the provision of online data insights via the MyCala.com patient portal that can be shared with healthcare providers.Key customers and partnershipsThe company’s key partners include the University of California, San Francisco to develop next-generation, smart neuromodulation therapies (in June 2021) and SK Biopharmaceuticals to explore new indications in neurology (May 2022).Funding and financialsIn November 2021, Cala Health raised USD 77 million in funding to expand patient access, expedite innovation, and accelerate partnerships with the payers. The proceeds were also used to enhance its product pipeline by adding further neurological conditions such as Parkinson’s disease as well as psychiatry, cardiology, and autoimmune disease therapies.

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

Thirty Madison offers direct-to-consumer telehealth consultations, online prescriptions, and treatment delivery for chronic conditions. The specialist treatment is offered for a range of illnesses via four brands; Keeps (for men’s hair loss), Cove (for migraines), Nurx (for sexual and reproductive health), and Facet (for dermatology care).As of <a href="https://www.prnewswire.com/news-releases/thirty-madison-delivers-continuity-of-care-for-thousands-through-strategic-asset-purchase-from-the-pill-club-strengthening-its-position-in-womens-health-301849594.html">June 2023</a>, the company’s telehealth platform had provided treatment for almost 1 million people.In <a href="https://www.prnewswire.com/news-releases/thirty-madison-and-nurx-to-merge-creating-the-leading-virtual-specialty-care-platform-301478752.html">February 2022</a>, the telehealth unicorn announced it planned to merge with a specialty care platform Nurx in an all-stock deal. The company planned to widen its portfolio of products and services under the Thirty Madison brand via the acquisition. The integrated platform catered to nearly 750,000 patients, offering a range of specialty care services from birth control to chronic disease management. The combined company planned to grow its B2B operations via partnerships with national payers and employers.&nbsp;In <a href="https://www.prnewswire.com/news-releases/thirty-madison-delivers-continuity-of-care-for-thousands-through-strategic-asset-purchase-from-the-pill-club-strengthening-its-position-in-womens-health-301849594.html">June 2023</a>, the company acquired assets from recently bankrupt online pharmacy provider The Pill Club in a deal valued at USD 32.3 million. The assets acquired include over 100,000 patient files, which will enable the company to provide continued care for those patients through its online birth control prescription plan, Nurx.Key customers and partnershipsIn <a href="https://www.prnewswire.com/news-releases/thirty-madisons-nurx-and-cove-partner-with-talkspace-to-expand-mental-health-support-for-more-than-half-a-million-women-302127466.html">April 2024</a> Thirty Madison partnered with Talkspace, an online therapy company, to bring mental health care to the former's members using its Nurx and Cove platforms. As part of the collaboration, Talkspace began providing therapy services to Nurx and Cove members via their respective platforms. While Nurx users already had access to treatments for depression and anxiety, along with medication management, the partnership provided Nurx and Cove members with the opportunity to connect with licensed therapists via Talkspace and benefit from its self-guided app. Talkspace users, on the other hand, were able to access migraine care from Cove and dermatological and reproductive health services for women from Nurx.

Transforming neurological care with innovation

Neurostimulation Tech

Cala Health is a bioelectronic medicine company that has developed the Cala kIQ system, a wearable neuromodulation device that delivers transcutaneous afferent patterned stimulation (TAPS) therapy for the relief of hand tremors in adults with essential tremor and Parkinson's disease. The Cala kIQ system comprises a stimulator, a band with integrated electrodes, and a base station. It utilizes a calibrated TAPS output pattern adjusted to match the patient's unique tremor frequency, providing personalized stimulation to the median and radial nerves of the wrist.
The Cala kIQ system received 510k clearance from the US Food and Drug Administration (FDA) in November 2022 and was launched for human use in June 2023. The device offers treatment sessions of 40 minutes, with a wristband life of 90 days and a shelf life of three months. Patients can review their therapy session results through the MyCala.com patient portal and share them with healthcare providers.
Cala Health has reported positive clinical data demonstrating the effectiveness of TAPS therapy in reducing tremors and improving activities of daily living for essential tremor patients. The company has secured reimbursement and coding from various commercial and government payors, including Medicare, to improve patient access to the therapy.

RNA Therapeutics

Accent Therapeutics is a biopharmaceutical company focused on developing small molecule precision cancer therapies. The company targets critical intracellular dependencies that span multiple types of cancer, with a particular emphasis on RNA-modifying proteins (RMPs) and adjacent high-value areas. Accent's lead program is a first-in-class DHX9 inhibitor, which aims to address high unmet need indications including BRCA loss of function cancers (breast, ovarian), mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) cancers (colorectal, endometrial, gastric), and other cancer types. DHX9 is a DNA/RNA helicase involved in various cellular processes, and its inhibition exploits key tumor vulnerabilities.
The company's second lead program is a potentially best-in-class KIF18A inhibitor. KIF18A is a mitotic kinesin motor protein critical for cell division in tumors with chromosomal instability. This inhibitor could potentially benefit patients with ovarian cancer and triple negative breast cancer (TNBC). Accent planned to initiate IND-enabling studies for KIF18A in the first half of 2024. In addition to these programs, Accent is developing inhibitors for other targets such as XRN1, ADAR1, and DHX9, which have shown promise in preclinical studies for various cancer indications.

Therapeutics that target specific areas/tissues to minimize treatment side effects.

Tissue Targeting Therapeutics

Aro Biotherapeutics is a clinical-stage biotechnology company based in Philadelphia that specializes in developing tissue-targeted genetic medicines. The company's core technology is a proprietary protein platform called Centyrins, which enables efficient and tissue-specific delivery of siRNA and other genetic drugs. Aro's lead candidate, ABX1100, is being developed for the treatment of Pompe disease, a rare genetic disorder characterized by toxic glycogen accumulation in muscles. ABX1100 comprises a CD71 receptor-binding Centyrin conjugated to a small interfering RNA (siRNA) that targets the Gys1 gene, reducing levels and activity of the Gys1 enzyme in muscle tissues. The therapy has shown promising results in preclinical studies, demonstrating potent and muscle-specific reductions in Gys1 mRNA and protein in the Pompe mouse model. In October 2023, Aro initiated a Phase 1 clinical trial of ABX1100 in Canada, with initial data expected in 2024. The US Food and Drug Administration granted ABX1100 Orphan Drug Designation and Rare Pediatric Disease status. Beyond Pompe disease, Aro is exploring the potential of its Centyrin-siRNA conjugate programs for developing new treatments for autoimmune disorders.

Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, and easy-to-use.

ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. It was founded in 2011 and is headquartered in Ann Arbor, Michigan.

Spectrawave is a medical device company that develops optical diagnostic and therapeutic devices. It enhances the diagnosis and treatment of cardiovascular diseases and primarily operates in the diagnostic equipment, medical business/industry. The Waltham, Massachusetts based company was founded in 2017.

HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

The InDx implant is the only implant that can fully mimic the natural but complex motions of the thumb joint. The device is also easier to insert and less invasive than any currently available surgical treatment option for this condition.

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.  Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).  Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases. The company's immunotherapies allow tissue and cell-specific targeting of the cytokine payload with the added potential for significantly enhanced efficacy.

Flindr Therapeutics, a private biotech company develops next-generation precision oncology treatments.

Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise.

Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.

Tempo Therapeutics develops materials that are immune stealth, minimally invasive, and precision-engineered for regenerative medicine. It provides power to regenerative medicine, providing materials that evade the typical host immune rejection response to build synthetic tissue hybrids from skin to bone to heart to brain.

Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen-presenting cells.

Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and differentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, they aim to translate extraordinary science into life-changing therapies for patients.

Nanobiotix SA develops nanomedicine programs for the treatment of cancer. The company provides NanoXray that offers a solution for cancer therapy based on a technology that is designed to allow destruction of cancer cells by inert particles. Its products include magnetic particles and laser activated nanoparticles for the treatment and diagnostic of cancer.

Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.

On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.

RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),  stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency.

Jurata Thin Film allows for the long-term storage of vaccines and biologics at room temperature or higher. Furthermore, therapeutic cargo stored in this thin film can be delivered via a variety of routes.

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.

Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience. The company focuses on how the immune system impacts CNS health, disease, and treatment.

Rapport Therapeutics operates as a clinical-stage biotechnology company, that discovers and develops precision medicines for neurological disorders. Rapport Therapeutics describes relationships that are defined by understanding, communication, teamwork, and trust.

CirCode Bio is an innovative biotechnology company focusing on the development of circular RNA nucleic acid drugs.

Ring Code Bio is a biomedical company that develops nucleic acid drugs based on a unique circular RNA technology platform.

Astraveus is revolutionizing the field of CGT manufacturing with the Lakhesys™ platform, an end-to-end, cell foundry, that uses deep process optimization and single-use, microfluidic bioprocessors to deliver better results with reduced inputs.   By removing the need for large-scale infrastructure, reducing costs, and overcoming the logistical challenges typically associated with CGT manufacturing, Astraveus is seeking to transform patient access to these life-changing therapies.

Solenic Medical, a medical device company that develops a non-invasive treatment for infected metallic implants in the body. The company leverages the properties of alternating magnetic fields (AMF) generated from external coils to eradicate biofilm on the surface of medical implants. This non-invasive treatment addresses a major complication of various surgeries, such as knee and hip replacements, as well as in trauma-related implants such as plates and rods. Its AMF technology has the potential to completely replace the very expensive and risky two-step revision surgical procedure, which is the current standard of care for chronic infections on medical implants. Rajiv Chopra and David Greenberg founded it in College Station, Texas in 2019.

Perceive Biotherapeutics is a biotechnology company pioneering novel technologies and therapeutics in ophthalmology.

Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. It aims to improve the lives and health of millions of people.

DocSpera is an integrated surgical coordination platform to help manage synchronization across multiple sites and teams, drive improved workflow efficiencies, and deliver better patient care. DocSpera’s proprietary platform automates pre-surgical coordination.  It offers real-time, compliant, secure case and image synchronization among all care delivery stakeholders: Surgeon, Care Team, and Device Supplier, using EHR data. DocSpera is part of Compliant Innovations Inc and headquartered in Sunnyvale, CA.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Rondo Therapeutics is a therapeutic antibody discovery and development that creates novel bispecific antibodies that activate the immune system to fight cancer. The company was founded in 2021 and is headquartered in Hayward, California.

Iterative Scopes delivers tools for physicians and life sciences in colorectal cancer and inflammatory bowel disease space. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Verana Health is a digital health data company that delivers insights from unfiltered healthcare data with integrity to connect the dots between patient care and clinical research. Verana Health is exclusively entrusted by key specialty medical societies to manage data from real-world healthcare settings across more than 20,000 healthcare providers and 70 electronic health record systems. Its healthcare data ecosystem is powered by VeraQ™, a clinician-directed and AI-enhanced population health data engine that securely powers a data integrity feedback loop of nearly a half-billion raw, point-of-care health encounters. By applying advanced analytics to proprietary, curated datasets, Qdata™, Verana Health helps life sciences partners enhance evidence generation and speed clinical research that promote physicians’ quality of care and patients’ quality of life. For more information, visit www.veranahealth.com.

V-Wave is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity, and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing, and bringing to market multiple implantable cardiovascular devices.

AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio®, has received clearance/approval for a wide range of applications in the United States and more than 40 countries around the World.

Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.

FlexDex is a minimally invasive surgery medical device technology that provides high dexterity. Its platform technology translates the surgeon’s hand, wrist, and arm movements from outside the patient into corresponding movements of an end-effector inside the patient’s body. The company was founded in 2010 and is headquartered in Brighton, Michigan.

Visus Therapeutics is a clinical-stage company developing innovative medicines to improve the vision for people around the world.

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.

Ribon Therapeutics is a biotechnology company pioneering the discovery of new cancer medicines that target monoPARP proteins, critical regulators of cancer survival mechanisms. The diverse and central functions that PARPs, or poly(ADP-ribose) polymerases, play in cancer cell survival pathways are just emerging, and many of the seminal discoveries in the field have been made by Ribon’s scientific founders. By combining insights from our founders and an experienced management team, Ribon is building a proprietary drug discovery platform to investigate the molecular action and biological function of a subset of the PARP protein family, called monoPARPs. Based on its platform, Ribon is creating a pipeline of innovative medicines that selectively target monoPARPs to treat cancer and may have the potential to impact other diseases. The company is backed by prominent life science investors, including The Column Group, U.S. Venture Partners, Deerfield Management and Osage University Partners.

Thirty Madison is a family of specialized healthcare brands devoted to creating exceptional outcomes for all. Each of its specialized brands is focused on a specific ongoing condition, and thoughtfully designed to support the unique needs of its community with personalized treatments and care; with Keeps for men's hair loss, Cove for migraine, Picnic for allergies, Facet for skin conditions, and NURX for sexual health. With empathy at the heart of its innovation, its proprietary care model empowers hundreds of thousands of people with ongoing conditions with the accessible, effective treatments across a lifetime of care. Learn more at ThirtyMadison.com.

Cue helps users track their health at the molecular level, revealing the interplay of activity, food, and sleep. Consumers can track five key health and lifestyle indicators: inflammation, vitamin D, fertility, influenza, and testosterone in just minutes, at home. The Cue sends the data via Bluetooth 4.0 to the user's smartphone, where the free Cue app reveals the interplay of activity, food, and sleep shaping the user at a molecular level.

Mestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology.

Sunday2Sunday is an emerging textured hair care company that focuses on bringing ingredients and products to its customer's doorstep. It specializes in the fields of beauty, healthcare, and consumer goods. It was founded in 2019 and headquartered in Brooklyn, New York.

TechsoMed is an Israeli based medical device company, developing ultrasound based real-time monitoring systems for thermal ablation procedures. The applications of thermal ablation are numerous: tumor destruction, heart arrhythmia, blood pressure treatments and more. The procedure has market size in the billions, but lacks real-time monitoring capabilities, causing high failure rates.   Their technology offers added value to patients, physicians and insurance companies by solving the high failure rate of these minimally invasive and cost effective procedures.

Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The Company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity.  Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, and minimize IT burden and costs while ensuring patient safety and data privacy. Paige’s products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.

Taza Aya specializes in non-thermal plasmas that use in a variety of industries and applications to remove and kill pathogens in the air. The company's headquarters are in Ann Arbor, Michigan.

Datavant is a data logistics company for healthcare whose products and solutions enable organizations to move and connect data securely. Datavant has a network of networks consisting of thousands of organizations, more than 70,000 hospitals and clinics, 70% of the 100 largest health systems, and an ecosystem of 500+ real-world data partners. To learn more about Datavant, visit datavant.com.

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.

XWPharma is a neuroscience biotech company that is researching new medicines for sleep, neuropsychiatric, and other neglected CNS illnesses. Bay Area, CA US.

Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases.  Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4.  E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.

Aetion delivers real-world evidence (RWE) and outcomes-based analytics solutions to life sciences companies, payers, and at-risk providers. With its patented rapid-cycle analytics technology, the Aetion Evidence Platform utilizes the everyday clinical and financial interactions of the healthcare system to unlock essential evidence about the effectiveness and value of medical treatments. Founded by Harvard Medical School faculty members and top big data technologists, Aetion enables payers and providers to collaborate with biopharmaceutical and medical device companies in real-time to develop therapeutic insights and make smart choices in inpatient care.  Aetion is based in New York City and backed by investors including New Enterprise Associates (NEA), Flare Capital Partners, Lakestar, Greenspring Associates, Town Hall Ventures, McKesson Ventures, Sanofi Ventures, EDBI, Amgen Ventures, Johnson & Johnson Innovation — JJDC, Inc., UCB, and Horizon Health Services, Inc.

G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reduce healthcare costs. G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system.   It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States.

ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer. It is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells. Cell surface-targeted immunotherapies, such as bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) T cells, generally target both cancer and normal cells, causing substantial toxicities and limiting their potential.  The company is taking a fundamentally novel approach to targeting cancer selectively by developing hematopoietic stem cells (HSCs) that have been engineered to be protected from specifically targeted immunotherapies. These HSCs are designed to generate healthy, functional cells that are also protected from depletion by cancer-targeted therapies.

GATT Technologies is a medical device company, developed a breakthrough patented synthetic technology intended to address severe and problematic surgical bleedings and organ leakages.

OrthoSpin is developing innovative robotic external fixation system that will improve patient treatment and allow a real-time review to reduce complications and improve clinical outcomes. Dynamic external fixators are mainly used for trauma, bone lengthening and congenital deformities correction. Those systems are cumbersome, painful and require high maintenance. With OrthoSpin’s smart system, physicians are assured that the prescribed course of treatment is being followed. The Company’s proprietary software program allows physicians to chart patient progress and, if required, to easily change the treatment schedule.

ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.

X-Vax Technology is a biotechnology company focused on the preclinical and clinical development of vaccines against pathogens that cause mucosal infections such as herpes, influenza, tuberculosis and HIV, affecting hundreds of millions of people around the globe. They believe that inducing antibodies that mediate the killing of infected cells will provoke an entirely new and effective immune response – so that they can finally beat these pathogens. The company was founded in 2015 and based in Jupiter, Florida.

Cara Care is a digital gut health platform that offers an app-based treatment to help patients with chronic gastrointestinal problems. It empowers patients suffering from chronic digestive diseases to enjoy a better life. Cara Care takes digestive health beyond the pill, bringing together behavioral, microbial, and nutritional data. Cara Care has already helped 700.000+ patients around the world with software-based medical devices.

BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.

Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its vertically integrated commercial model is reshaping the delivery of prescription therapies. Cala Health’s lead product, Cala Trio™ therapy, is the only non-invasive prescription therapy for essential tremor. New therapies are under development in Parkinson’s disease and other indications in neurology, as well as targets in psychiatry, cardiology, and autoimmune disorders. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company. It is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production center. Fusion’s deep radiochemistry expertise presents a technology platform that can be replicated to turn internalizing antibodies that have previously demonstrated limited clinical efficacy into highly effective cytotoxic drugs. Fusion’s ability to link effective isotopes to the targeting antibody allows for the creation of optimized agents for both diagnostic imaging and radioimmunotherapy (Precision Medicine). Following positive tumor identification with the imaging agent, treatment with the antibody linked to a therapeutic isotope delivers a cytotoxic payload into the cancer cell. Fusion’s lead product candidate, FPX-01, is a precision RIT that is a product of this innovative approach. FPX-01 has been designed to internalize targeted cancer cells and deliver a lethal and highly localized radioactive payload. The precise targeting of this radiolabeled antibody causes selective and extremely effective cytotoxicity of tumor cells at relatively low doses of radioactivity.

Memebox Corporation is a consumer company that provides customers with the Asian beauty products, culture, and trends. A global company focused on forecasting trends and creating private, in-house labels inspired by K-beauty (and made for the product obsessed).

Countless industries have innovated by shifting to real-time operations. MultiScale Hive brings the vision of a real-time health system (RTHS) to healthcare. Hive empowers clinicians with the EHR data and insights needed to solve problems as they happen. With Hive, health systems gain a customer-first, RTHS infrastructure that improves care delivery outcomes, patient engagement and operational efficiency.

Pivot’s unique six-stage program is designed to engage smokers earlier than other cessation plans, without pressuring them to quit. It begins by helping them become more aware of their smoking and more confident in their ability to do something about it. Then, for those who decide they’re ready, Pivot helps them build and execute a quit plan, with one-on-one coaching support until their quit is stable.

CuraSen Therapeutics is a biopharmaceutical company that develops orphan drugs to treat neurodegenerative diseases, including Parkinson's disease, and Alzheimer's disease.

PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity, and ease of administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects, and better patient compliance. Efficient production in E. coli ensures a low cost of goods. PhaseBio’s lead drug candidate, PB1023, is currently being evaluated in a phase 2b clinical trial for the treatment of hyperglycemia associated with type 2 diabetes, with potential for future use in the treatment of obesity. Our second drug candidate, Vasomera, is currently being evaluated in phase 1 clinical trial and has exciting potential for use in the treatment of pulmonary arterial hypertension (PAH) and heart failure. Its third program, Insumera, basal insulin based on native human insulin, will enter clinical trials in early 2013. PhaseBio is based in Malvern, Pennsylvania.

S-Biomedic brings novel therapeutic solutions to the skin microbiome.The skin microbiome - a habitat of billions of beneficial and harmful bacteria - contributes to healthy skin. An imbalance of these bacteria can lead to a variety of skin conditions including acne, eczema, rosacea and ageing. S-Biomedic uses a targeted modulation-based technology to modify the skin microbiome. This technology can be applied in both the dermatology and cosmetic industries. They design their products using the latest advances in microbiology and dermatology. Using their technology, beneficial bacteria are selected and combined to generate products that accelerate the rebalancing of a disease microbiome. In this way, they are able to restore a healthy state back to your skin.

Zebra Medical Vision’s imaging analytics platform allows healthcare institutions to identify patients at risk of disease and offer improved preventative treatment pathways to advance patient care. The company is funded by Khosla Ventures, Marc Benioff, Intermountain Investment Fund, OurCrowd Qure, Aurum, aMoon, Nvidia, J&J, and Dolby Ventures. Zebra Medical Vision has raised $52 million in funding to date and was named a Fast Company Top-5 AI and Machine Learning company. Zebra-Med leads the way in AI FDA cleared products, and is installed in hospitals globally, from Australia to India, Europe to the U.S, and the LATAM region.

NeuroVision is an integrated neuroscience company focused on delivering scientifically validated, diagnostic tests & biomarkers for early detection and monitoring of amyloid pathology related to Alzheimer’s Disease.   The company has developed a novel retinal imaging technology, which is currently being utilized in a number of clinical trials globally.With access to unique datasets, we provide data aggregation services, analysis, biostatistics, and applications of machine learning algorithms to large repositories of images and other biomarker data seeking to advance the collective understanding and prediction capabilities for neurodegenerative diseases.

Protagonist Therapeutics is a biotechnology company dedicated to the discovery of novel peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions.

Johnson & Johnson Innovation accelerates early-stage innovation through strategic collaboration. It connects potential collaborators to resources with the goal of assisting them in advancing transformation science and technology across the pharmaceutical, medical device, and consumer healthcare spectrums.

Johnson & Johnson Innovation – JJDC

Portfolio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless